CEL-SCI (NYSE:CVM) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Wednesday morning. The firm issued a sell rating on the stock.

CEL-SCI Price Performance

CVM opened at $0.37 on Wednesday. The firm has a market cap of $24.33 million, a P/E ratio of -0.63 and a beta of 0.65. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64. CEL-SCI has a fifty-two week low of $0.36 and a fifty-two week high of $3.08. The firm has a 50-day moving average of $0.63 and a 200 day moving average of $0.95.

Institutional Investors Weigh In On CEL-SCI

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Thoroughbred Financial Services LLC boosted its stake in CEL-SCI by 140.9% in the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after buying an additional 80,001 shares in the last quarter. Black Diamond Financial LLC boosted its stake in shares of CEL-SCI by 35.8% in the 2nd quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock valued at $84,000 after purchasing an additional 19,000 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of CEL-SCI by 29.9% during the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after purchasing an additional 40,000 shares during the last quarter. Calton & Associates Inc. purchased a new stake in shares of CEL-SCI during the third quarter valued at approximately $50,000. Finally, Plotkin Financial Advisors LLC bought a new position in CEL-SCI during the 3rd quarter valued at approximately $98,000. 12.08% of the stock is currently owned by institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.